Activating p53 and Inhibiting Superenhancers to Cure Leukemia

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Superenhancers (SEs) are crucial for oncogene expression in cancer.
• Targeting SE-driven transcription is a potential therapeutic strategy for leukemia.
• p53 pathway dysregulation is common in various cancers, including leukemia.

Purpose of the Study:

• To identify novel molecules that inhibit key kinases involved in cancer cell survival.
• To investigate the therapeutic potential of combining p53 activation with SE inhibition.
• To evaluate the efficacy of this combined strategy in promoting leukemic cell death.

Main Methods:

• Synthesis and screening of novel small molecules.
• Biochemical assays to measure kinase inhibition (CK1α, CDK7, CDK9).
• Analysis of p53 activation and downstream effects.
• Assessment of SE-driven transcription inhibition.
• In vitro studies on leukemic cell lines to evaluate cell killing efficacy.

Main Results:

• Identification of novel molecules inhibiting CK1α, CDK7, and CDK9.
• Demonstration of p53 activation by these molecules.
• Preferential inhibition of superenhancer-driven transcription.
• Synergistic killing of leukemic cells when combining p53 activation and SE suppression.

Conclusions:

• Novel inhibitors of CK1α, CDK7, and CDK9 activate p53 and suppress SE-driven transcription.
• This dual-action strategy effectively promotes cooperative killing of leukemic cells.
• The findings present a promising therapeutic approach for leukemia.